ATE539758T1 - Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen - Google Patents

Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen

Info

Publication number
ATE539758T1
ATE539758T1 AT09007997T AT09007997T ATE539758T1 AT E539758 T1 ATE539758 T1 AT E539758T1 AT 09007997 T AT09007997 T AT 09007997T AT 09007997 T AT09007997 T AT 09007997T AT E539758 T1 ATE539758 T1 AT E539758T1
Authority
AT
Austria
Prior art keywords
bcr
fusion gene
abl fusion
abl
rnai modulation
Prior art date
Application number
AT09007997T
Other languages
English (en)
Inventor
Philipp Hadwiger
Hans-Peter Vornlocher
Der Kuip Heiko Van
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE539758T1 publication Critical patent/ATE539758T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT09007997T 2004-11-24 2005-11-23 Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen ATE539758T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63087804P 2004-11-24 2004-11-24
US63240304P 2004-12-01 2004-12-01

Publications (1)

Publication Number Publication Date
ATE539758T1 true ATE539758T1 (de) 2012-01-15

Family

ID=36647951

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09007997T ATE539758T1 (de) 2004-11-24 2005-11-23 Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen

Country Status (7)

Country Link
US (4) US20060287264A1 (de)
EP (2) EP2133081B1 (de)
JP (2) JP2008521401A (de)
AT (1) ATE539758T1 (de)
AU (1) AU2005323303A1 (de)
CA (1) CA2587697A1 (de)
WO (1) WO2006073602A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109376A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting bcr-abl gene expression and uses thereof
WO2008112292A1 (en) 2007-03-13 2008-09-18 Optimedica Corporation Apparatus for creating ocular surgical and relaxing incisions
ITRM20070595A1 (it) * 2007-11-15 2009-05-16 Univ Roma Mirna e sirna e loro uso in terapia
US20110071214A1 (en) * 2008-05-14 2011-03-24 Gregory John Allen Methods and compositions for the treatment of cancer
JP5875976B2 (ja) 2009-06-01 2016-03-02 ヘイロー−バイオ アールエヌエーアイ セラピューティクス， インコーポレイテッド 多価ｒｎａ干渉のためのポリヌクレオチド、組成物およびそれらの使用方法
MX2018002090A (es) 2015-08-24 2018-09-12 Halo Bio Rnai Therapeutics Inc Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
CN106987599B (zh) * 2017-03-28 2021-06-11 重庆医科大学 一种抑制人bcr-abl融合基因表达或导致人bcr-abl基因功能丧失的锌指核酸酶及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1992022303A1 (en) * 1991-06-18 1992-12-23 Temple University - Of The Commonwealth System Of Higher Education Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
HU230458B1 (hu) 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
EP1386004A4 (de) 2001-04-05 2005-02-16 Ribozyme Pharm Inc Modulation der mit der entzündungsausbreitung und dem neuritenauswuchs assoziierten genexpression unter verwendung von technologien auf nukleinsäurebasis
WO2003070972A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030130186A1 (en) * 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US20050159381A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
ATE479752T1 (de) 2003-03-07 2010-09-15 Alnylam Pharmaceuticals Inc Therapeutische zusammensetzungen
AU2004232964B2 (en) 2003-04-17 2011-09-22 Alnylam Pharmaceuticals, Inc. Protected monomers
EP2669377A3 (de) * 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modifizierte iRNA-Wirkstoffe
AU2005247509C1 (en) 2004-05-27 2012-09-20 Alnylam Pharmaceuticals, Inc. Nuclease resistant double-stranded ribonucleic acid

Also Published As

Publication number Publication date
EP1814597A2 (de) 2007-08-08
AU2005323303A1 (en) 2006-07-13
US20110251263A1 (en) 2011-10-13
US7994307B2 (en) 2011-08-09
US20060287264A1 (en) 2006-12-21
EP1814597A4 (de) 2009-04-22
US20080293662A1 (en) 2008-11-27
EP2133081A1 (de) 2009-12-16
US20100234446A1 (en) 2010-09-16
WO2006073602A3 (en) 2007-11-22
JP2008521401A (ja) 2008-06-26
EP2133081B1 (de) 2012-01-04
WO2006073602A2 (en) 2006-07-13
WO2006073602A9 (en) 2006-09-28
JP2011201927A (ja) 2011-10-13
CA2587697A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
ATE544774T1 (de) Rnai-modulation von mll-af4 und verwendungen dafür
WO2006036916A3 (en) Rnai modulation of apob and uses thereof
WO2005044976A3 (en) Oligomeric compounds for use in gene modulation
WO2007014077A3 (en) Rnai modulation of the rho-a gene and uses thereof
NO20081884L (no) Modulasjon av glukagonreseptorekspresjon
EA200800868A1 (ru) Модуляция экспрессии глюкокортикоидного рецептора
WO2004005460A3 (en) Antisense modulation of hmg-coa reductase expression
WO2005027962A3 (en) 4’-thionucleosides and oligomeric compounds
ATE539758T1 (de) Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen
WO2006020768A3 (en) Chemically modified oligonucleotides
EP1569695A4 (de) Antisense-modulationder apolipoprotein-b-expression
EP1828219A4 (de) Sirna-silencing von apolipoprotein b
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
MXPA06012796A (es) Ciertas entidades quimicas, composiciones y metodos.
DE602007013559D1 (de) Nanoteilchen zur abgabe von nukleinsäure
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
WO2005049630A3 (en) Antisense modulation of kinesin-like 1 expression
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
WO2007056469A3 (en) Certain chemical entities, compositions, and methods
WO2007056143A3 (en) Certain chemical entities, compositions, and methods
WO2007056078A3 (en) Certain chemical entities, compositions, and methods
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2005049832A3 (en) FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION